Aurobindo Pharma gets USFDA nod for infection treatment drug
Team Udayavani, Jul 11, 2018, 4:24 PM IST
New Delhi: Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Azithromycin tablets, used for the treatment of patients with mild to moderate infections, in the US market.
The approval has been granted in the strengths of 250 mg and 500 mg, and the product will be launched this month, Aurobindo Pharma said in a BSE filing.
The approved product is generic equivalent of Pfizer Inc’s Zithromax tablet, it added.
Quoting IQVIA sales data, the company said, the approved product has an estimated market size of USD 132 million for the 12 months ending May 2018.
Aurobindo Pharma currently has a total of 337 ANDA approvals (344 final approvals including 17 from Aurolife Pharma and 35 tentative approvals) from the US.
Stock of Aurobindo Pharma was trading 0.06 per cent lower at Rs 616.90 on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
RBI: After another status quo year, all eyes on a growth-propping rate cut with new Guv at helm
Front-running case: Sebi bans 9 entities from market , impounds illegal gains of over Rs 21 crore
Global trends, FIIs’ move to dictate trends in markets in holiday-shortened week: Analysts
GST Council postpones decision to cut tax on insurance, rate panel defers report submission
GST Council meet to decide on lower taxes on insurance policies, ATF inclusion
MUST WATCH
Latest Additions
Kannada Sahitya Sammelana: Food distribution creates stir
Rohit gets hit in nets, practice pitches on slower side
India & Kuwait elevate ties to strategic level; ink defence pact after PM Modi meets top Kuwaiti leaders
In Kuwait, PM Modi meets yoga practitioner, other influencers from Gulf country
Notorious gangster wanted in UAPA case arrested at Nepal border
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.